November 2021 - Page 9 of 10

FridayNov 05, 2021 9:00 am

FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF) CEO Discusses Importance of Company’s New Additions to the Management Team

September 2021 saw four new additions to FuelPositive’s management team Each of the new appointments brings with them decades of experience, technical know-how and strategic approaches that will guide the company’s future decisions and investments Ian Clifford, FuelPositive’s CEO and chair, has acknowledged that some of these appointments have come at “just the right time” Ian Clifford, the chief executive officer and chair of the board at FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), while appearing in an interview on the company’s YouTube channel, expressed his optimism and enthusiasm about four new appointments the company made over the month of September. “It’s just a great day for us to add to our…

FridayNov 05, 2021 9:00 am

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Validates its AI-Driven Drug Discovery Program with Successful Synthesis of Novel Tryptamine; Confirms Participation in the Wonderland: Miami Psychedelic Medicine Business Event

Mydecine just announced the successful synthesis of a novel psilocin analogue, a tryptamine The achievement adds to the company’s library of patent-pending tryptamines for medical use and therapy, and is seen as verifying the value of Mydecine’s AI-driven drug discovery program Mydecine has also confirmed its participation in the Wonderland: Miami psychedelic medicine event scheduled for November 8-9, 2021, where the company will share its recent research advancements and goals going forward Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) just announced the successful synthesis of a novel psilocin analogue, a tryptamine, that has proven to have improved pharmaceutical properties (https://nnw.fm/hRZoX).…

FridayNov 05, 2021 8:52 am

InnerScope Hearing Technologies Inc. (INND) Leverages Outstanding Leadership Team to Bring New Disruptive Products and Expand Market Reach

INND appears committed to creating a leadership dream team announcing Adnan Shennib as the Company's CTO and president of international operations Shennib is a proven leader and entrepreneur in hearing medical devices; he developed several commercially successful hearing innovations INND is poised to leverage Shennib's invaluable insight and expertise to develop new disruptive products and expand Company's partnerships around the world InnerScope Hearing Technologies (OTC: INND) has announced that Adnan Shennib, a seasoned industry professional, will join as chief technology officer ("CTO") and the president of international operations responsible for expanding the Company's partnerships with manufacturers, distributors, and innovators worldwide. …

ThursdayNov 04, 2021 1:02 pm

Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) Experiencing Massive Growth Ahead of American Gaming Association’s Bullish 2022 Prediction

American Gaming Association’s Gaming CEO Outlook expects industry growth in 2020 driven by new hiring, wage growth, and capital investment PLGNF sees explosive growth in October 2021 with a 1500% betting handle increase, and betting turnover reached approximately $1.6 million per day from $53,500 for September PLGNF’s IP-protected iGaming software solutions include Live Dealer Casino, E-Table Games, Daily Fantasy Sports PLGNF applications run securely on any browser without app store download, do not require sharing sensitive data Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF), a SaaS technology company focused on developing and licensing digital content for the growing global iGaming market,…

ThursdayNov 04, 2021 12:48 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Marks Another Significant Milestone with IND Application for Fibromyalgia Phase 2a Clinical Trial

Tryp just filed an IND with the FDA for its TRP-8802 clinical candidate for its Phase 2a clinical trial The trial is set to commence in 2022, subject to a favorable review by the FDA The study will be conducted in collaboration with the University of Michigan and will aim at evaluating the safety and clinical utility of psilocybin for fibromyalgia Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced its submission of an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (“FDA”) for its TRP-88802 clinical candidate. This application follows the commencement of Tryp’s Phase…

ThursdayNov 04, 2021 12:15 pm

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Growth Strategy Moves Forward with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) Partnership for Ketamine-Assisted Psychotherapy Distribution

The distribution component unlocks a new revenue source for the company, helping drive future growth MINDCURE’s platform was built as a digital tool and distribution platform, and has already been used for deployment and distribution of ketamine for depression and pain Digital therapeutics market is projected to reach USD $13.1 billion by 2026 from USD $3.4 billion in 2021 at a CAGR of 31.4 %, a substantial increase primarily driven by the COVID-19 pandemic and the stressors associated with it MINDCURE’s target areas and value proposition list numerous benefits for therapists, patients, payers, and drug and protocol developers, through the…

ThursdayNov 04, 2021 9:42 am

Friendable Inc. (FDBL) Welcomes ShamirMuzik, Plans Case Study to Highlight His Fan Pass Platform Journey Through End of Year

The case study based on ShamirMuzik and his journey will serve as a means of showing how Fan Pass can help increase artist reach, revenue, and visibility The platform’s November contest can earn artists up to $175 ($150 for streaming + $25 for Instagram promotion) by performing live five times during the month Fan Pass has released its first fall merchandise line, with a limited time offering consisting of ten new designs donning over 20 new color choices Mobile technology and marketing company Friendable (OTC: FDBL) announced the addition of ShamirMuzik to the company’s Fan Pass Live Streaming artist platform…

WednesdayNov 03, 2021 1:43 pm

The Cannabis World Congress & Business Exposition (CWCBExpo) Is Set to Headline the New York Cannabis Week; Will Bring Together Hundreds of Businesses from Across the Cannabis Ecosystem

The Cannabis World Congress & Business Exposition (CWCBExpo) will be held in New York between November 4-6, 2021 The conference will feature over 50 expert speakers, in addition to hundreds of exhibitors showcasing the sector’s latest product innovations Recent forecasts have estimated overall US marijuana retail sales to rise from $20 billion in 2020 to $38.4-45.9 billion by 2025 The Cannabis World Congress & Business Exposition (“CWCBExpo”) event is set to be held at New York City’s Javits Convention Center, Hall 3A between 4-6 November 2021. Set to be held during Cannabis Week, a weeklong event taking place between Monday…

WednesdayNov 03, 2021 1:24 pm

FingerMotion Inc. (FNGR) Adding More Value to Core Communications Services with Mobile Device Protection Brands

U.S.-based FingerMotion is a communications technology services company focused on the enormous Chinese consumer base and its adoption of mobile devices FingerMotion has established its operations on a stable tripod of services including SMS, MMS, and big data technologies The company recently reported growing revenues derived primarily from its SMS and MMS products On Oct. 25 the company introduced two new brands for value-added services that will help underwrite protection plans for mobile devices during the coming year FingerMotion expects its big data platform Sapientus to eventually outstrip SMS and MMS revenues as it becomes a significant tool for establishing…

WednesdayNov 03, 2021 12:30 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology’s Efficacy in Reducing/Inhibiting Seizure Activity; Strengthens IP Portfolio

Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD has similar or superior efficacy in reducing or inhibiting seizure activity compared to FDA-approved seizure drug, Epidiolex The study will also compare DehydraTECH-CBD to generic CBD EPIL-A21-1 has entered early-stage preparatory work, with results expected in Q3 2022 Lexaria received new patent awards in Mexico and Japan, strengthening its IP portfolio to 23 granted patents Lexaria Bioscience (NASDAQ: LEXX), the drug delivery platform innovator behind the disruptive, patented DehydraTECH(TM) technology, recently announced it had commenced an important new animal study, EPIL-A21-1 (https://nnw.fm/u0RXj). EPIL-A21-1, which will be…

Financial news and publishing for public and private companies

Contact us: 212.418.1217

Month: November 2021